详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

87| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University [2]Shanxi Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Taiyuan, 030032, China [3]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China [4]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China [5]Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China [6]Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

出处：

DOI：

ISSN：

关键词： COVID-19 cytokine release syndrome JAK inhibitors

摘要：

Recent advances in the pathophysiologic understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc. Therefore, the treatment of cytokine storm has been proposed as a critical part of rescuing severe COVID-19. Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clinical outcomes in COVID-19. Below, we review the possibilities and challenges of targeting the pathway in COVID-19. © 2020 Elsevier Ltd

基金：

语种：

高被引：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2019]版中科院分区表Review为是的期刊

：

大类 | 1 区

医学

小类 | 1 区药学

最新[2025]版

：

大类 | 1 区

医学

小类 | 1 区药学

JCR分区：

出版当年[2018]版：

Q1 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q1 PHARMACOLOGY & PHARMACY

影响因子： 13.9 最新[2023版] 14.3 最新五年平均 11.523 出版当年[2018版] 12.709 出版当年五年平均 12.108 出版前一年[2017版] 13.503 出版后一年[2019版]

第一作者：

第一作者单位： [1]Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University [2]Shanxi Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Taiyuan, 030032, China

共同第一作者：

通讯作者：

通讯机构： [1]Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Shanxi Medical University [2]Shanxi Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Taiyuan, 030032, China [5]Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 [2]Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? [3]Targeting TNF-α for COVID-19: Recent Advanced and Controversies [4]CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges [5]癫痫患者精神共患病与新型冠状病毒肺炎 [6]Letter to the editor regarding a meta-analysis of JAK inhibitors and psoriatic arthritis [7]新型冠状病毒肺炎患者血清白细胞介素2R测定及其评价 [8]嵌合抗原受体修饰T细胞免疫疗法治疗B细胞恶性肿瘤患者的护理 [9]Macrophage, the potential key mediator in CAR-T related CRS [10]智能医学时代的新发重大传染病预警、应对和医院运营优化——COVID-19疫情防控思考

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19 $(function () { $("[data-toggle='tooltip']").tooltip(); });

文献详情

相关文献

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19